Candida glabrata PDR1, a transcriptional regulator of a pleiotropic drug resistance network, mediates azole resistance in clinical isolates and petite mutants - PubMed (original) (raw)

Candida glabrata PDR1, a transcriptional regulator of a pleiotropic drug resistance network, mediates azole resistance in clinical isolates and petite mutants

Huei-Fung Tsai et al. Antimicrob Agents Chemother. 2006 Apr.

Abstract

Candida glabrata, a yeast with intrinsically low susceptibility to azoles, frequently develops increased azole resistance during prolonged treatment. Transposon mutagenesis revealed that disruption of CgPDR1 resulted in an 8- to 16-fold increase in fluconazole susceptibility of C. glabrata. CgPDR1 is a homolog of Saccharomyces cerevisiae PDR1, which encodes a transcriptional regulator of multidrug transporters. Northern blot analyses indicated that CgPDR1 regulated both constitutive and drug-induced expression of CgCDR1, a multidrug transporter gene. In agreement with the Northern analysis, the Cgpdr1 mutant had increased rhodamine accumulation, in contrast to the decreased accumulation in the CgPDR1-overexpressing strain. Northern analyses also indicated the importance of CgPDR1 in fluconazole resistance arising during therapy. Two clinically resistant isolates had higher expression of CgPDR1 and CgCDR1 compared to their paired susceptible isolates. Integrative transformation of CgPDR1 from the two resistant isolates converted the Cgpdr1 mutant into azole-resistant strains with upregulated CgPDR1 expression. Two different amino acid substitutions, W297S in one isolate and F575L in the other, accounted for the upregulated CgPDR1 expression and the resistance. Finally, CgPDR1 was shown to be required for the azole resistance due to mitochondrial deficiency. Thus, CgPDR1 encodes a transcriptional regulator of a pleiotropic drug resistance network and contributes to the azole resistance of clinical isolates and petite mutants.

PubMed Disclaimer

Figures

FIG. 1.

FIG. 1.

Southern hybridization analysis confirmed the disruption and targeted replacement of PDR1 in C. glabrata. (A) Restriction enzyme map. (B) Southern blot analysis. Total DNA was digested with BglII. The membrane was hybridized with the 2.9-kb Tn_5_ (left panel) or 1.3-kb BglII Cg_PDR1_ (right panel) probe. Lanes: 1, strain NCCLS84, C. glabrata laboratory wild-type strain; 2, strain CgB4, Cg_pdr1_ mutant; 3, strain Cg173C, CgB4 complemented with Cg_PDR1_ of clinical fluconazole-resistant isolate Cg13928. An asterisk indicates the codon mutations in the clinical fluconazole-resistant isolates, W297S in Cg4672 and F575L in Cg13928.

FIG. 2.

FIG. 2.

Overexpression of Cg_PDR1_ in the pdr1 mutant of S. cerevisiae reduced its sensitivities to fluconazole and rhodamine 6G. A disk diffusion assay was used to determine the drug sensitivities of S. cerevisiae strains. Strains: BY4741, wild type; 4381, pdr1 mutant; 4381/pH392, pdr1 mutant carrying the vector pH392; 4381/pHCgPDR1, pdr1 mutant carrying the Cg_PDR1_ overexpression cassette ADH1p _-Cg_PDR1-ADH1T. FLC, fluconazole; R6G, rhodamine 6G. Plates were photographed after 2 days of incubation at 30°C. WT, wild type.

FIG. 3.

FIG. 3.

Disruption or overexpression of Cg_PDR1_ altered the expression of Cg_CDR1_ and PDH1. Northern hybridization analyses were used to determine the expression of Cg_PDR1_, Cg_CDR1_, and PDH1. Ten micrograms of total RNA was used for Northern blot analysis. The membrane was hybridized with the following probe: 2.3-kb BglII Cg_PDR1_ DNA (top panel), 1.1-kb NotI-BamHI Cg_CDR1_ DNA from pCRScript-CDR1 (14) (middle panel), or 3.6-kb PDH1 DNA from pClaI (25) (bottom panel). Sizes of putative transcripts are indicated in kilobases on the right. The rRNA stained with ethidium bromide was used as the loading control. Lanes: 1, strain NCCLS84, wild type; 2, strain CgB4, Cg_pdr1_ mutant; 3, strain CgB4/pCgACU, Cg_pdr1_ mutant carrying the vector pCgACU; 4, strain CgB4/pCgPDR1, Cg_pdr1_ mutant overexpressing Cg_PDR1_. WT, wild type.

FIG. 4.

FIG. 4.

Cycloheximide- and oligomycin-induced Cg_CDR1_ expression depended on Cg_PDR1_. Ten micrograms of total RNA was used for the Northern hybridization analysis to determine the level of drug-induced Cg_CDR1_ expression. The membrane was hybridized with the 1.1-kb NotI-BamHI Cg_CDR1_ DNA probe. The sizes of putative transcripts are indicated in kilobases. The rRNA stained with ethidium bromide was used as the loading control. Lanes: 1 to 4, NCCLS84 (wild type); 5 to 8, CgB4 (Cg_pdr1_ mutant). CHX, cycloheximide; OLI, oligomycin; R6G, rhodamine 6G. WT, wild type.

FIG. 5.

FIG. 5.

Altered drug sensitivity in C. glabrata caused by the disruption or overexpression of Cg_PDR1_. Disk diffusion assay was used to determine the drug sensitivity of C. glabrata. Strains: NCCLS84, wild type; 84870, Cg_cdr1_ and pdh1 double disruptant; CgB4, Cg_pdr1_ mutant; CgB4u/pCgACU, Cg_pdr1_ carrying the vector pCgACU; CgB4u/pCgPDR1, Cg_pdr1_ mutant overexpressing Cg_PDR1_. FLC, fluconazole; R6G, rhodamine 6G; CHX, cycloheximide; CHL, chloramphenicol; CRN, cerulenin. Plates were photographed after 2 days of incubation at 30°C. WT, wild type.

FIG. 6.

FIG. 6.

Clinical fluconazole-resistant isolates overexpressed Cg_PDR1_ and Cg_CDR1_. Two pairs of clinical isolates, Cg1660 versus Cg4672 and Cg12581 versus Cg13928, were analyzed by Northern blot hybridization along with NCCLS84. Probes used for each Northern blot are labeled on the left, and the estimated sizes of hybridized transcripts in kilobases are labeled on the right. The rRNA stained with ethidium bromide was used as the loading control. Probes: top, 2.3-kb Bgl_II Cg_PDR1 DNA; bottom, 1.1-kb NotI-BamHI Cg_CDR1_ DNA.

FIG. 7.

FIG. 7.

W297S or F595L single-amino-acid substitution of CgPdr1p led to upregulated expression of Cg_PDR1_ and Cg_CDR1_. The expression of Cg_PDR1_ and Cg_CDR1_ was analyzed by Northern blot analysis. The membrane was hybridized with the 2.9-kb HindIII Cg_PDR1_ DNA or 1.1-kb NotI-BamHI Cg_CDR1_ DNA probe. The rRNA stained with ethidium bromide was used as the loading control. All complementations were done with integrative transformation. (A) Lanes: 1, strain NCCLS84, wild type; 2, strain CgB4, Cg_pdr1_ mutant; 3 and 4, strain CgB4Ca12581 and strain CgB4Cb12581, CgB4 complemented by Cg_PDR1_ from Cg12581; 5 and 6, strain CgB4Ca13928 and strain CgB4Cb13928, CgB4 complemented by Cg_PDR1_ from Cg13928. (B) Lanes: 1, strain NCCLS84, wild type; 2, strain CgB4, Cg_pdr1_ mutant; 3 and 4, strain CgB4Ca1660 and strain CgB4Cb1660, CgB4 complemented by Cg_PDR1_ from Cg1660; 5 and 6, strain CgB4Ca4672 and strain CgB4Cb4672, CgB4 complemented by Cg_PDR1_ from Cg4672. WT, wild type.

FIG. 8.

FIG. 8.

Cg_PDR1_ is required for upregulated expression of PDR genes caused by mitochondrial dysfunction. For Northern blot analysis, the membrane was hybridized with the 2.3-kb BglII Cg_PDR1_ DNA (top) or 2.3-kb BamHI-NotI Cg_CDR1_ (bottom) probe. The rRNA stained with ethidium bromide was used as the loading control. Lanes: 1, strain NCCLS84, wild type; 2 and 3, petite mutant strains derived from NCCLS84; 5, strain CgB4, Cg_pdr1_ mutant; 6 to 8, petite mutant strains derived from CgB4.

Similar articles

Cited by

References

    1. Balzi, E., W. Chen, S. Ulaszewski, E. Capieaux, and A. Goffeau. 1987. The multidrug resistance gene PDR1 from Saccharomyces cerevisiae. J. Biol. Chem. 262:16871-16879. - PubMed
    1. Bennett, J. E., K. Izumikawa, and K. A. Marr. 2004. Mechanism of increased fluconazole resistance in Candida glabrata during prophylaxis. Antimicrob. Agents Chemother. 48:1773-1777. - PMC - PubMed
    1. Brachmann, C. B., A. Davies, G. J. Cost, E. Caputo, J. Li, P. Hieter, and J. D. Boeke. 1998. Designer deletion strains derived from Saccharomyces cerevisiae S288C: a useful set of strains and plasmids for PCR-mediated gene disruption and other applications. Yeast 14:115-132. - PubMed
    1. Brun, S., C. Aubry, O. Lima, R. Filmon, T. Berges, D. Chabasse, and J. P. Bouchara. 2003. Relationships between respiration and susceptibility to azole antifungals in Candida glabrata. Antimicrob. Agents Chemother. 47:847-853. - PMC - PubMed
    1. Brun, S., T. Berges, P. Poupard, C. Vauzelle-Moreau, G. Renier, D. Chabasse, and J. P. Bouchara. 2004. Mechanisms of azole resistance in petite mutants of Candida glabrata. Antimicrob. Agents Chemother. 48:1788-1796. - PMC - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources